JP2019527236A - 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 - Google Patents

癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 Download PDF

Info

Publication number
JP2019527236A
JP2019527236A JP2019506400A JP2019506400A JP2019527236A JP 2019527236 A JP2019527236 A JP 2019527236A JP 2019506400 A JP2019506400 A JP 2019506400A JP 2019506400 A JP2019506400 A JP 2019506400A JP 2019527236 A JP2019527236 A JP 2019527236A
Authority
JP
Japan
Prior art keywords
immunomodulator
cancer
administered
combination
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019506400A
Other languages
English (en)
Japanese (ja)
Inventor
ピー．ハート チャールズ
ピー．ハート チャールズ
Original Assignee
モレキュラー テンプレーツ，インコーポレイティド
モレキュラー テンプレーツ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モレキュラー テンプレーツ，インコーポレイティド, モレキュラー テンプレーツ，インコーポレイティド filed Critical モレキュラー テンプレーツ，インコーポレイティド
Publication of JP2019527236A publication Critical patent/JP2019527236A/ja
Priority to JP2022144394A priority Critical patent/JP2022189827A/ja
Priority to JP2025165723A priority patent/JP2025185043A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019506400A 2016-08-01 2017-07-26 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 Pending JP2019527236A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022144394A JP2022189827A (ja) 2016-08-01 2022-09-12 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
JP2025165723A JP2025185043A (ja) 2016-08-01 2025-10-01 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369691P 2016-08-01 2016-08-01
US62/369,691 2016-08-01
PCT/US2017/044002 WO2018026606A1 (en) 2016-08-01 2017-07-26 Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022144394A Division JP2022189827A (ja) 2016-08-01 2022-09-12 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与

Publications (1)

Publication Number Publication Date
JP2019527236A true JP2019527236A (ja) 2019-09-26

Family

ID=61073118

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019506400A Pending JP2019527236A (ja) 2016-08-01 2017-07-26 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
JP2022144394A Pending JP2022189827A (ja) 2016-08-01 2022-09-12 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
JP2025165723A Pending JP2025185043A (ja) 2016-08-01 2025-10-01 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022144394A Pending JP2022189827A (ja) 2016-08-01 2022-09-12 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
JP2025165723A Pending JP2025185043A (ja) 2016-08-01 2025-10-01 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与

Country Status (4)

Country Link
US (1) US20210369746A1 (cg-RX-API-DMAC10.html)
EP (2) EP4549467A3 (cg-RX-API-DMAC10.html)
JP (3) JP2019527236A (cg-RX-API-DMAC10.html)
WO (1) WO2018026606A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109999183B (zh) * 2019-04-15 2021-03-09 中国科学技术大学 一种含有乏氧激活前药的纳米簇化酶及其制备方法和应用
WO2023025291A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
JP7762796B2 (ja) 2021-08-27 2025-10-30 アセンタウィッツ ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
EP4509127A4 (en) 2022-04-15 2026-07-15 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD USING TH-302 ALONE OR IN COMBINATION WITH A PARP INHIBITOR
EP4529926A4 (en) 2022-05-23 2026-07-01 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
EP4674418A1 (en) 2023-02-27 2026-01-07 Ascentawits Pharmaceuticals, Ltd. Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method
EP4755396A1 (en) 2023-07-28 2026-06-10 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients
CN121985960A (zh) 2023-10-18 2026-05-05 深圳艾欣达伟医药科技有限公司 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506448A (ja) * 2008-10-21 2012-03-15 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 低酸素活性化型プロドラッグを用いるがんの処置
WO2016054555A2 (en) * 2014-10-03 2016-04-07 Novartis Ag Combination therapies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
ZA200800314B (en) 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8552048B2 (en) 2006-12-26 2013-10-08 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US8962808B2 (en) * 2010-05-05 2015-02-24 The Research Foundation For The State University Of New York EGFR-related polypeptides and methods of use
AU2011276590A1 (en) * 2010-06-28 2013-01-31 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
WO2013116385A1 (en) * 2012-01-31 2013-08-08 Threshold Pharmaceuticals, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
PL3099717T3 (pl) * 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
WO2015191568A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506448A (ja) * 2008-10-21 2012-03-15 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 低酸素活性化型プロドラッグを用いるがんの処置
WO2016054555A2 (en) * 2014-10-03 2016-04-07 Novartis Ag Combination therapies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. 74(19 Supplement), JPN6021025169, 2014, pages 629, ISSN: 0004957528 *
JOURNAL OF IMMUNOTOXICOLOGY, vol. 9(3), JPN6021025168, 2012, pages 241 - 247, ISSN: 0004957529 *

Also Published As

Publication number Publication date
JP2022189827A (ja) 2022-12-22
EP3490548A1 (en) 2019-06-05
EP4549467A2 (en) 2025-05-07
EP3490548A4 (en) 2020-04-15
EP4549467A3 (en) 2025-07-23
JP2025185043A (ja) 2025-12-18
US20210369746A1 (en) 2021-12-02
WO2018026606A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
JP2022189827A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
US20250152708A1 (en) Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
US20240018257A1 (en) Antibodies specific to human poliovirus receptor (pvr)
JP2023130496A (ja) 癌治療のための併用療法
KR20170003575A (ko) 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
RS56531B1 (sr) Kombinacija dr5 agoniste i anti-pd-1 antagoniste i načini primene
JP2019516712A (ja) 癌を処置するためのグルタミン酸調節剤と免疫療法の併用
JP6892443B2 (ja) がん治療で使用するためのチェックポイント阻害剤及び全細胞マイコバクテリウム
KR20180041623A (ko) 소마토스타타틴 수용체를 과발현하는 신경내분비 종양의 치료방법
TWI771372B (zh) Wnt抑制劑與抗-pd-1抗體分子組合之給藥方案
WO2022103904A1 (en) Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
TWI812820B (zh) 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法
EP3930719B1 (en) Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
HK40125832A (en) Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
WO2021214623A1 (en) Dosing regimen for treating a disease modulated by csf-1r
WO2021009761A1 (en) Combination therapy for the treatment of cancer
RU2830077C2 (ru) Введение ингибитора sumo-активирующего фермента и ингибиторов контрольных точек
HK40015605A (en) Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule
EA042223B1 (ru) Фармацевтическая композиция для лечения инфекционного заболевания или рака

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20190319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220912

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220912

C12 Written invitation by the commissioner to file intermediate amendments

Free format text: JAPANESE INTERMEDIATE CODE: C12

Effective date: 20220927

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221212

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221213

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230113

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250123